Kiniksa Pharmaceuticals Files 8-K Report

TL;DR

Kiniksa Pharma filed a routine 8-K on 6/14/24, updating corporate info. No major news.

AI Summary

On June 14, 2024, Kiniksa Pharmaceuticals, Ltd. filed an 8-K report. The filing indicates that the company is incorporated in Bermuda and provides its principal executive office address in Hamilton, Bermuda, with a US contact address in Lexington, MA. The report does not detail specific events but is a standard filing for the date.

Why It Matters

This filing serves as a notification to the SEC and investors about the company's corporate structure and contact information, which is standard for public companies.

Risk Assessment

Risk Level: low — This is a routine corporate filing with no new material information or events disclosed.

Key Players & Entities

• Kiniksa Pharmaceuticals, Ltd. (company) — Registrant
• June 14, 2024 (date) — Date of earliest event reported
• Bermuda (location) — State of incorporation
• 001-38492 (other) — Commission File Number
• 98-1327726 (other) — I.R.S. Employer Identification No.
• Clarendon House (location) — Address of principal executive offices
• 2 Church Street (location) — Address of principal executive offices
• Hamilton HM11 (location) — Address of principal executive offices
• Kiniksa Pharmaceuticals Corp. (company) — US contact entity
• 100 Hayden Avenue (location) — US contact address

FAQ

Key Financial Figures

• $0.000273235 — ich registered Class A Common Shares $0.000273235 par value KNSA The Nasdaq Stock Mar

Filing Documents

• tm2417321d1_8k.htm (8-K) — 27KB
• 0001104659-24-071787.txt ( ) — 197KB
• knsa-20240614.xsd (EX-101.SCH) — 3KB
• knsa-20240614_lab.xml (EX-101.LAB) — 33KB
• knsa-20240614_pre.xml (EX-101.PRE) — 22KB
• tm2417321d1_8k_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. As previously announced, Kiniksa Pharmaceuticals, Ltd. (the "Company" and, together with its consolidated subsidiaries, "Kiniksa") intends to change the place of incorporation of Kiniksa's principal holding company from Bermuda to the United Kingdom (the "Redomiciliation"). On June 14, 2024, the Supreme Court of Bermuda issued an order sanctioning the scheme of arrangement between the Company and its shareholders, which had been approved by the Company's shareholders of record entitled to notice of and to vote at the Company's special court-ordered meeting of shareholders on June 5, 2024. The Company expects the Redomiciliation to take effect on or around June 27, 2024.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements. All statements other than statements of historical facts contained in this Current Report on Form 8-K including statements with respect to the business of Kiniksa and the Redomiciliation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "goal," "design," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. The forward-looking statements in this Current Report on Form 8-K are only predictions. We have based these forward-looking statements largely on our current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including without limitation, the following: our ability to satisfy the other conditions to the Redomiciliation on the expected timeframe, or at all, our ability to realize the expected benefits from the Redomiciliation and the occurrence of unanticipated difficulties or costs in connection with the Redomiciliation.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINIKSA PHARMACEUTICALS, LTD. Date: June 14, 2024 By: /s/ Madelyn Zeylikman Madelyn Zeylikman Senior Vice President, General Counsel and Secretary